Gilead to Stop Phase 3 Study 116 of Idelalisib... - CLL Support
Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia Early Because of Positive Risk- Benefit
You need to be a member of this community to see this post.
Read more about...
12 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies
online June 13, 2019.
Key Points
* In 424 patients with CLL on long-term ibrutinib, AEs were...
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Update on The CLARITY Study
have some members who are in this important CLARITY Study in UK.
CLARITY is a phase II trial that...
An Early Look at When CAR-T Therapy Fails Patients With CLL
and characteristics of patients with CLL who received anti-CD19 CAR-T therapy during a clinical...
Breaking news form ASH conference: looks like Ibrutinib May be better than FCR for some patients
#ASH18 #LBA | A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard...
Mode of Progression After Frontline Treatment Predicts Clinical Outcomes in Patients With CLL
000 patients from three German CLL Study Group clinical trials has identified that unfit patients...
Related Posts
- Progression Free Survival (PFS) post Discontinuation of Ibrutinib in E1912 Trial
- Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL
Incorrect Interpretation of BTKis & Incidence of SPM- UK NICE Approves Ibrutinib +Venetoclax for First Line treatment for ALL Patients from today
- Time-Limited Triplet Emerges as a Potential Standard in Relapsed/Refractory CLL
